NCT03278470View on ClinicalTrials.gov

A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

March 19, 2018

Study Completion Date

March 19, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

HL237

Experimental

DRUG

Placebo Oral Tablet

placebo with same properties except for active ingredient

Trial Locations (1)

Unknown

The catholic university of korea seoul ST. mary's hospital, Soeul

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03278470 - A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject | Biotech Hunter | Biotech Hunter